Biogen Idec News

Analysts at Wells Fargo & Co. assumed coverage on shares of Biogen Idec in a research report issued to clients and investors on Monday.

Tallahassee, FL 2/10/12 - Biotechnology topics are hot in the investment community.

Seattle Genetics, Inc. A will unveil its latest earnings on Monday, February 13, 2012.A The average estimate of analysts is for a loss of 30 cents per share, a narrower loss from the year earlier quarter net loss of 34 cents.

In the following article I analyze my five best ideas from the S&P 500 , based on their fourth-quarter and annual financial results for 2011.

Research analysts at Morgan Stanley initiated coverage on shares of Biogen Idec in a report issued on Friday.

Biogen Idec Inc. announced today that its presentation at the Leerink Swann Global Healthcare Conference will be webcast live on Wednesday, February 15, 2012 at 8:30 a.m. ET.

Perhaps it is true that any press is good press. No one likes bad press, especially when others in the same field are receiving positive press.

Below is a list of five strong biotechs with great future prospects that have delivered positive earnings surprises recently, and are certainly worth a look.

Local drug maker Biogen Idec is dedicating 10 electric car rechargers this morning at its facility in Research Triangle Park as part of the federal government's subsidization push for electric cars.

Local drug maker Biogen Idec is dedicating 10 electric car rechargers this morning at its facility in Research Triangle Park.

Despite some commentators predicting a muted or near nonexistent market for advanced biosimilars, many companies - and some surprising names - are positioning themselves for market entry.

Sobi and Biogen Idec have agreed to disclose further details on their agreement regarding development and commercialization of long-lasting recombinant factor VIII and factor IX hemophilia programs, which was restructured in February 2010.

Biogen Idec was pleased to announce last week that the FDA has approved an update to the prescription labeling of their monthly IV monoclonal antibody medication for multiple sclerosis known as Tysabri .

All signs point to emerging biotech company Rainbow Coral Corp. finding its feet in biotechnology at exactly the right time: The biotech industry is off to a great start in the early stages of 2012.

Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.

Cunliffe, who will also join the board of directors, will be responsible for program evaluation and selection as well as growth plans for the company.

Biogen Idec Inc. may ultimately join Amgen Inc. as biotechnology companies that pay a dividend, Chief Financial Officer Paul Clancy said.

Phase III data Anticipated in 2012 for Long-Lasting Factor VIII and Factor IX in Hemophilia and Dexpramipexole in ALS -- WESTON, Mass.-- --Jan 31, 2012 - Biogen Idec Inc.

Biogen Idec 's stock had its "neutral" rating reaffirmed by equities research analysts at Robert W. Baird in a research note issued to investors on Tuesday.

S&P 500 component Biogen IDEC Inc reported its results for the fourth quarter. Biogen Idec is a global biotechnology company that meets the rising needs of therapeutic care providers and recipients.